Results 291 to 300 of about 714,188 (330)

Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE₂ signaling pathway in mice. [PDF]

Front Immunol
Sakurai K, Chubachi S, Miyata J, Hamamoto J, Naganuma T, Shimada T, Otake S, Nakayama S, Irie H, Tsutsumi A, Kameyama N, Hegab AE, Shimoda M, Terai H, Yasuda H, Kanai Y, Arita M, Fukunaga K.   +17 more
europepmc   +1 more source

COX-2 in lung cancer: Mechanisms, development, and targeted therapies. [PDF]

Chronic Dis Transl Med
Liu X, Zhang J, Sun W, Cao J, Ma Z.
europepmc   +1 more source

Erratum: miR-137 represses migration and cell motility by targeting COX-2 in non-small cell lung cancer. [PDF]

Transl Cancer Res
Editorial Office.
europepmc   +1 more source

COX‐2 inhibitors [PDF]

Medical Journal of Australia, 2000
Cyclooxygenase-2 (COX-2) inhibitors constitute a new group of non-steroidal anti-inflammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not by cyclooxygenase-1. Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once ...
Brooks, P. M., Day, R. O.
openaire   +5 more sources